{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-26-000047","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2026-05-20T00:08:52+00:00","discovered_at":"2026-05-20T10:05:00.298147+00:00","generated_at":"2026-05-20T10:07:50.828609+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Krystal Biotech shareholders approve all four proposals at 2026 annual meeting","bullets":["Elected Krish S. Krishnan and Christopher Mason as Class III directors with ~89% and ~84% of votes cast.","Ratified KPMG as independent auditor for FY2026 with over 99.9% of votes in favor.","Advisory vote on named executive officer compensation passed with ~95.5% of votes cast.","Approved non-employee director compensation policy with ~90% of unaffiliated votes cast."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-26-000047","json":"https://secwatch.observer/filing/0001711279-26-000047.json","markdown":"https://secwatch.observer/filing/0001711279-26-000047.md","text":"https://secwatch.observer/filing/0001711279-26-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000047/0001711279-26-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000047/krys-20260515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T10:07:50.828609+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c8035d02e7f01b82fbf2c76525695ab9947c537","claim":"Krystal Biotech, Inc. shareholders approved Election of Class III Directors at the 2026-05-15 meeting.","evidence_excerpt":"The Company’s stockholders elected Krish S. Krishnan and Christopher Mason as members of the Company’s Board of Directors as Class III directors for a three-year term. The results of the vote were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Krish S. Krishnan 23,802,920 3,079,194 1,581,473 Christopher Mason 22,581,854 4,300,260 1,581,473","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000047/0001711279-26-000047-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-15"}],"fact_type":"shareholder_vote"},{"claim_id":"8eed43653ac8d639929325ace1445559bd1f212c","claim":"Krystal Biotech, Inc. shareholders approved Non-Employee Director Compensation Policy at the 2026-05-15 meeting.","evidence_excerpt":"The Company’s unaffiliated stockholders (i.e., excluding the members of the the Company’s board of directors and the defendants in the litigation entitled Corbin v. Janney, et al. , C.A. No. 2025-1051-KSJM (Del. Ch.) who refrained from voting on this matter in their capacities as stockholders) approved the Company’s Non-Employee Director Compensation Policy. The results of the vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 21,374,021 2,349,550 3,158,543 1,581,473","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000047/0001711279-26-000047-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-15"}],"fact_type":"shareholder_vote"},{"claim_id":"9a068a48a183a3718667de61ab6c81e35b941bbc","claim":"Krystal Biotech, Inc. shareholders approved Non-Binding, Advisory Vote on Named Executive Officer Compensation at the 2026-05-15 meeting.","evidence_excerpt":"The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2025, as disclosed in the Company’s proxy statement for the Annual Meeting pursuant to the compensation disclosure rules of the Securities and Exchange Commission. The results of the vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 25,679,318 1,195,788 7,008 1,581,473","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000047/0001711279-26-000047-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-15"}],"fact_type":"shareholder_vote"},{"claim_id":"d808e227474fc6e74108561d1a2e4c7f771fd834","claim":"Krystal Biotech, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-15 meeting.","evidence_excerpt":"The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the vote were as follows: Votes For Votes Against Abstentions 28,443,155 15,434 4,998","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000047/0001711279-26-000047-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-15"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}